Closing the paediatric gap in cancer drug development: a call to industry
Branko Cuglievan
Nature Reviews Drug Discovery, Published online: 29 May 2026; doi:10.1038/d41573-026-00089-3 Despite transformative advances in adult oncology, children with cancer remain systematically underserved by drug development pipelines. We argue that sequential, siloed paediatric development is no longer defensible. Integrating paediatric considerations from drug discovery onwards, and leveraging tumour-agnostic trial designs, regulatory frameworks and adaptive methodologies, offers sponsors superior s